Integral Health Asset Management LLC Boosts Position in Rezolute, Inc. (NASDAQ:RZLT)

Integral Health Asset Management LLC grew its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 100.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 500,000 shares of the company's stock after acquiring an additional 250,000 shares during the quarter. Integral Health Asset Management LLC owned about 0.86% of Rezolute worth $2,450,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its holdings in shares of Rezolute by 699.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock valued at $12,377,000 after purchasing an additional 2,210,038 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rezolute by 749.0% in the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock valued at $4,379,000 after purchasing an additional 788,349 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $2,408,000. Nantahala Capital Management LLC increased its holdings in shares of Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after purchasing an additional 280,861 shares during the last quarter. Finally, J. Goldman & Co LP acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $1,140,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on RZLT. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday, February 10th. JMP Securities lifted their target price on Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Rezolute in a research report on Wednesday. Craig Hallum raised Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a report on Monday, April 28th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $12.14.

Insider Buying and Selling at Rezolute

In related news, Director Wladimir Hogenhuis acquired 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the completion of the transaction, the director now owns 77,267 shares in the company, valued at $363,154.90. This represents a 14.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the purchase, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 39,060 shares of company stock valued at $130,694 in the last three months. 18.39% of the stock is owned by corporate insiders.

Rezolute Stock Up 1.3%

NASDAQ RZLT traded up $0.05 during trading on Friday, hitting $3.61. The stock had a trading volume of 718,136 shares, compared to its average volume of 838,476. The company has a market capitalization of $218.23 million, a PE ratio of -2.95 and a beta of 1.01. The firm has a 50 day moving average price of $3.24 and a 200 day moving average price of $4.32. Rezolute, Inc. has a twelve month low of $2.21 and a twelve month high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, sell-side analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.